OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Recommendation of “Hold” from Brokerages

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) have received a consensus recommendation of “Hold” from the five brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $6.00.

Several equities research analysts have commented on OKYO shares. B. Riley Financial initiated coverage on shares of OKYO Pharma in a research note on Monday, December 8th. They issued a “buy” rating and a $5.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of OKYO Pharma in a research note on Thursday, January 29th. Piper Sandler started coverage on OKYO Pharma in a research report on Friday. They set an “overweight” rating and a $7.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of OKYO Pharma in a report on Thursday, January 22nd.

Institutional Investors Weigh In On OKYO Pharma

Hedge funds have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in OKYO Pharma in the 4th quarter worth about $36,000. Renaissance Technologies LLC increased its stake in OKYO Pharma by 235.0% in the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after acquiring an additional 96,800 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in OKYO Pharma during the third quarter valued at approximately $31,000. Institutional investors own 2.97% of the company’s stock.

OKYO Pharma Price Performance

Shares of OKYO opened at $1.76 on Friday. OKYO Pharma has a 52 week low of $1.03 and a 52 week high of $3.35. The stock has a 50 day moving average price of $2.12 and a two-hundred day moving average price of $2.24.

OKYO Pharma (NASDAQ:OKYO) last announced its earnings results on Friday, January 30th. The company reported ($2.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($2.21). On average, equities analysts anticipate that OKYO Pharma will post -0.17 earnings per share for the current year.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.